Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

GRAIL Inc. (GRAL)

NASDAQ: GRAL · Services-Medical Laboratories · Sunnyvale, CA

Our rating: Cautious

Cautious reaffirmed at $124.74, high conviction, November 10, 2026.

Breaks if: The Cautious call turns wrong if the November 2026 patent invalidation is fully reversed on appeal and GRAIL reports two consecutive quarters of revenue growth above 30% year-over-year within the following 12 months — both conditions together would signal the IP risk has cleared and commercial momentum is genuine enough to begin compressing the revenue multiple toward something defensible.

Key figures

Market value$4.5B
Revenue, last 12 months$167M
Net income, last 12 months−$406M
Free cash flow, last 12 months−$312M
Price to earningsn/a
Free cash flow yield−7.0%
Dividend yield0.0%
Operating margin−347.3%
Return on equity−17.3%
Beta to the S&P 5002.36
Volatility, annualized104.1%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$38M3.7%$-2.21−$79M
June 30, 2026$45M25.7%$-2.56−$81M
March 31, 2026$41M28.1%$-2.29−$87M
December 31, 2025$44M14.0%$-2.38−$64M
September 30, 2025$36M26.3%$-2.46−$64M
June 30, 2025$36M11.2%$-3.18−$77M
March 31, 2025$32M19.1%$-3.10−$95M
December 31, 2024$38M26.1%$-1.93−$94M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

39 ledger entries and 10 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.